Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

SafeSEQ HNSCC assay

Sysmex Corp
Laboratory Developed Test
Related tests:


The HNSCC-SEQ Panel is an ultra-sensitive liquid biopsy solution for the identification of gene mutations in CDKN2A, EGFR, ERBB2, FGFR3, HRAS, KRAS, NOTCH1, PIK3CA, PTEN, and TP53 for emerging Head and Neck Squamous Cell Cancer (HNSCC) clinical applications. The HNSCC-SEQ Panel has been designed for human papillomavirus (HPV)-negative patients (~75% of HNSCC patients) and can be used to detect novel therapeutic targets and frequently occurring driver mutations for treatment response monitoring. The HNSCC-SEQ Panel delivers high-sensitivity mutation detection in HNSCC with a limit of detection of 0.05% MAF. Reliable detection of low-frequency mutations directly impacts the cost of clinical development.
Squamous Cell Carcinoma of Head and Neck
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), EGFR (Epidermal growth factor receptor), FGFR3 (Fibroblast growth factor receptor 3), HER-2 (Human epidermal growth factor receptor 2), HRAS (Harvey rat sarcoma viral oncogene homolog), KRAS (KRAS proto-oncogene GTPase)
See More ...
Next-Generation Sequencing (NGS) / Liquid biopsy